ALTESA
Altesa is a clinical-stage biopharmaceutical company dedicated to accelerating the development of new treatments against age-old threats to human health: high-consequence viral pathogens.
ALTESA
Social Links:
Industry:
Biotechnology Life Science Therapeutics
Founded:
2022-01-01
Address:
College Park, Georgia, United States
Country:
United States
Website Url:
http://www.altesabio.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
35 M USD
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Nivalis Therapeutics
Nivalis Therapeutics is a clinical-stage pharmaceutical company developing a novel class of disease modifying therapies.
Precision For Medicine
Precision for Medicine is the first global, precision-medicine, clinical research organization.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapyโbased treatments for cardiovascular disease.
TCR2
TCR2 is a discovery stage pharmaceutical company that developed a unique proprietary TRuCโข platform.
Current Employees Featured
Founder
Official Site Inspections
http://www.altesabio.com
- Host name: ec2-3-217-116-166.compute-1.amazonaws.com
- IP address: 3.217.116.166
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149

More informations about "Altesa"
Home - Altesa BioSciences
Altesa is a clinical-stage pharmaceutical company dedicated to developing new treatments for age-old threats to human health: high-consequence viral infections. These infections are particularly severe in vulnerable people, including those โฆSee details»
Leadership - Altesa BioSciences
Our leadership team is a highly successful and uniquely experienced group of clinicians, scientists, corporate executives, and investment professionals. Our focus: deliver novel โฆSee details»
Leadership - altesabio.com
Erica specializes in employee relations, employee engagement, and HR compliance. She believes that the employee experience correlates with the success of the organization; โฆSee details»
Altesa - Crunchbase Company Profile & Funding
Altesa is a clinical-stage biopharmaceutical company dedicated to accelerating the development of new treatmentsSee details»
Altesa BioSciences, Inc. | LinkedIn
Altesa BioSciences, Inc. | 694 followers on LinkedIn. Developing antivirals for diseases of global concernSee details»
Altesa Biosciences - VentureRadar
Dansk Biotek Unknown n/a DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, development and โฆSee details»
Altesa BioSciences Announces Scientific Advisory Board
Feb 28, 2022 Altesa BioSciences, Inc., a clinical-stage biopharmaceutical company developing and commercializing novel anti-viral drugs against common respiratory viruses and global viral โฆSee details»
Leadership - Altesa Bio
Altesa.com John M. Clerici, JD is a co-founder and Chief Operating Oficer of Altesa. As the founding Principal of Tiber Creek Partners, LLC, John has been a leader in public health โฆSee details»
Altesa BioSciences - PitchBook
Mar 21, 2022 Information on valuation, funding, cap tables, investors, and executives for Altesa BioSciences. Use the PitchBook Platform to explore the full profile.See details»
Overview, News & Similar companies - ZoomInfo.com
May 24, 2022 View Altesa BioSciences (www.altesabio.com) location in Georgia, United States , revenue, industry and description. Find related and similar companies as well as employees โฆSee details»
Altesa BioSciences, Inc., Launches Operations to Develop
Feb 10, 2022 Altesa BioSciences, Inc., an independently operated, for-profit biotechnology company today launched operations to develop and commercialize novel anti-viral drugs โฆSee details»
Altesa BioSciences Announces Scientific Advisory Board
Feb 28, 2022 Altesa BioSciences, a clinical-stage biopharmaceutical company developing novel anti-viral drugs, announced members of its Scientific Advisory Board.See details»
Opportunity - Altesa BioSciences
COPD is the third leading cause of death worldwide, according to the World Health Organization, and it is expected to become the #1 cause of death worldwide within 15 years.See details»
Altesa BioSciences, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Altesa BioSciences, Inc. with its drug pipeline, therapeutic area, technology platform, 3 clinical trials, 1 news, Disease Domain:Infectious Diseases ...See details»
Altesa BioSciences Recognizes Co-Founder and Partner for Major โฆ
May 25, 2022 Altesa BioSciences recognizes co-founder George Painter, PhD, for major research grant that will establish a new antiviral drug discovery center.See details»
Altesa Biosciences - CipherBio
Explore Altesa Biosciences's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
Microsoft Word - NR_ALTESA_LAUNCHES_OPS_02.10.2022_final.docx
Feb 10, 2022 1930 Harvard Street, College Park, GA 30337 I Altesabio.com George Painter, PhD, CEO of DRIVE, a discoverer of Molnupiravir and co-founder of Altesa, will serve as Chair โฆSee details»
Altesa BioSciences, Inc., Launches Operations to Develop, โฆ
Feb 10, 2022 ATLANTA-- (BUSINESS WIRE)--Altesa BioSciences, Inc., an independently operated, for-profit biotechnology company today launched operations to develop and โฆSee details»
Altesa BioSciences to Initiate Clinical Trials of Promising ... - BioSpace
May 26, 2022 Altesa BioSciences, Inc. (Altesa), a clinical-stage biopharmaceutical company developing and commercializing novel antiviral drugs against common respiratory viruses and โฆSee details»
Altesa Biosciences Recognizes Co-Founder and Partner for Major โฆ
May 25, 2022 George Painter, Emory Professor and CEO of DRIVE, awarded $52 million to co-lead Antiviral Countermeasures Development Center ATLANTA, May 25, 2022 โ Altesa โฆSee details»